Northern 2 VCT PLC
05 June 2007
5 JUNE 2007
NORTHERN 2 VCT PLC
INTERIM MANAGEMENT STATEMENT
FOR THE QUARTER ENDED 30 APRIL 2007
Northern 2 VCT PLC presents its interim management statement for the quarter
ended 30 April 2007. This constitutes the company's first interim management
statement for the financial year ending 31 January 2008, as required by the UK
Listing Authority's Disclosure and Transparency Rule 4.3.
The unaudited net asset value per ordinary share as at 30 April 2007 was 90.2p
(31 January 2007 88.9p). The net asset value is stated before deducting the
final dividend of 4.5p per share in respect of the year ended 31 January 2007,
which was approved by shareholders at the annual general meeting on 17 May 2007
and will be paid on 8 June 2007.
The number of ordinary shares in issue at 30 April 2007 was 47,851,696. During
the three months ended 30 April 2007 no shares were issued and a total of
422,316 shares were re-purchased by the company for cancellation at an average
price of 78.9p per share.
Net assets at 30 April 2007 comprised the following:
% of
£000 net assets
Unquoted investments at fair value
as determined by the directors 29,202 67.6
Quoted investments at bid price 3,166 7.3
------------ -----------
Total venture capital investments 32,368 74.9
Listed fixed-interest investments 7,163 16.6
------------ -----------
Total fixed asset investments 39,531 91.5
Net current assets 3,652 8.5
------------ -----------
Net assets 43,183 100.0
------------ -----------
The ten largest investments by valuation at 30 April 2007 were as follows:
% of
£000 net assets
Longhirst Group 2,208 5.1
John Laing Partnership 1,943 4.5
Envirotec 1,903 4.4
Crantock Bakery 1,802 4.2
IG Doors 1,300 3.0
TFB Group 1,201 2.8
DMN 1,145 2.7
Arrow Industrial Group 1,134 2.6
KCS Global Holdings 1,037 2.4
Liquidlogic 1,014 2.3
------------ -----------
Top ten investments 14,687 34.0
Other investments 17,681 40.9
------------ -----------
Total venture capital investments 32,368 74.9
------------ -----------
Quoted investments are carried at bid price as at 30 April 2007. Unquoted
investments are carried at fair value as at 30 April 2007 as determined by the
directors.
During the three months ended 30 April 2007 the following significant investment
transactions took place (all companies unquoted except where otherwise
indicated):
New investments:
Amount
Name of company Business activity invested
£000
Gentronix Drug development support services 173
Promanex Group Holdings Engineering and maintenance services 1,000
Vastox (AIM)* Drug discovery 220
Disposals:
Carrying
Sales Original value at
Name of company proceeds cost 31 January 2007
£000 £000 £000
Arrow Therapeutics 325 298 325
Computer Software Group (AIM) 1,832 442 1,400
Daniolabs* 220 145 244
PM Group (AIM) 257 175 197
*The holding in Vastox was acquired in a share-for-share exchange on the
acquisition of Daniolabs by Vastox
Enquiries:
Alastair Conn/Christopher Mellor, NVM Private Equity Limited - 0191 244 6000
Website: www.nvm.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.